[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Capelli M, Bertino G, Morbini P, Proh M, Falco CE, Benazzo M: CO2 laser in the treatment of laryngeal synovial sarcoma: a clinical case. Tumori; 2007 May-Jun;93(3):296-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CO2 laser in the treatment of laryngeal synovial sarcoma: a clinical case.
  • Synovial sarcoma is a rare mesenchymal neoplasm that is usually located in the limbs.
  • Its occurrence in the head and neck region, and particularly in the larynx, is exceptional, with only 16 cases reported to date.
  • Immunohistochemistry is determinant in the differential diagnosis between synovial sarcoma and other spindle and biphasic neoplasms.
  • The treatment of choice is conservative surgery with tumor-free margins, while radiotherapy is effective in local control of the disease after recurrence.
  • Chemotherapy is indicated for the treatment of distant metastases.
  • We present a case of monophasic synovial sarcoma of the laryngeal ventricle that was successfully treated with CO2 laser excision and we briefly review the literature on the subject.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Laser Therapy / methods. Sarcoma, Synovial / surgery
  • [MeSH-minor] Carbon Dioxide. Diagnosis, Differential. Humans. Male. Middle Aged. Voice Disorders / etiology

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679468.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  • [Number-of-references] 38
  •  go-up   go-down


2. Bilgic B, Mete O, Oztürk SA, Demiryont M, Keles N, Basaran M: Synovial sarcoma: a rare tumor of larynx. Pathol Oncol Res; 2003;9(4):242-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma: a rare tumor of larynx.
  • Synovial sarcoma is a soft tissue sarcoma of unknown histogenesis and occurs predominantly in the lower extremities of young adults.
  • There are about 10 cases with laryngeal localization in the literature.
  • Incisional biopsy and the hemilaryngectomy material revealed a biphasic synovial sarcoma.
  • The patient received chemotherapy for 6 courses.
  • The metastases responded well to chemotherapy and the patient is now alive without tumor on radiological and clinical examination after 3.5 years of follow-up.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Sarcoma, Synovial / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Immunohistochemistry. Laryngectomy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Radiotherapy

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1984 Sep;94(9):1158-61 [6088920.001]
  • [Cites] Med Pediatr Oncol. 1994;23(1):64-8 [8177148.001]
  • [Cites] Laryngorhinootologie. 1994 Aug;73(8):442-4 [7945664.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2001 Jun;21(3):192-7 [11677847.001]
  • [Cites] Acta Orthop Scand Suppl. 2000 Apr;291:1-28 [10862210.001]
  • [Cites] Arch Otolaryngol. 1980 Jan;106(1):8-12 [6928099.001]
  • [Cites] Arch Otolaryngol. 1975 Oct;101(10):633-6 [169770.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1809-14 [10468301.001]
  • [Cites] Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol. 1975 Sep-Oct;80(5):448-51 [173067.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1998 Dec;107(12):1080-5 [9865642.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1991;53(2):116-9 [1849243.001]
  • [Cites] Head Neck. 1989 Jan-Feb;11(1):76-80 [2537802.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(8):357-66 [9332890.001]
  • [Cites] Vestn Otorinolaringol. 1985 Mar-Apr;(2):61-2 [2988174.001]
  • [Cites] Ann Pathol. 2001 Feb;21(1):71-5 [11223565.001]
  • [Cites] Virchows Arch. 1999 Oct;435(4):407-12 [10526004.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1983;100(1):61-5 [6303187.001]
  • (PMID = 14688831.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


3. Pisani F, Marino M, Sentinelli S, Petti MC: Follicular dendritic cell sarcoma of the neck: report of a case treated by surgical excision and COP plus (PEG)-liposomal doxorubicin. J Exp Clin Cancer Res; 2008;27:33
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell sarcoma of the neck: report of a case treated by surgical excision and COP plus (PEG)-liposomal doxorubicin.
  • BACKGROUND: Follicular dendritic cell (FDC) sarcoma is a rare neoplasm arising in lymph nodes but also in extranodal sites from accessory cells of the immune system that are essential for the function of antigen presentation and germinal center reaction regulation.
  • FDC sarcoma has a significant recurrent and metastatic potential and for these reason it should be viewed as an intermediate grade malignancy.
  • Immunohistochemically, tumor cells were diffusely positive for follicular dendritic cell markers CD21, CD23 and negative for cytokeratin.The patient after complete excision of the lymph node underwent five courses of adjuvant chemotherapy with COP plus PEG-liposomal doxorubicin, considering the propensity of the tumor to metastasize.
  • CONCLUSION: These results suggest that this therapeutic modality may be useful in the management of FDC sarcoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Dendritic Cell Sarcoma, Follicular / therapy. Doxorubicin / therapeutic use. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Lymph Nodes / pathology. Middle Aged. Receptors, Complement 3d / immunology. Receptors, IgE / immunology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1986 Mar;122(3):562-72 [2420185.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):237-49 [12908776.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):144-54 [9606805.001]
  • [Cites] Am J Hematol. 1998 Oct;59(2):161-7 [9766802.001]
  • [Cites] J Pak Med Assoc. 2006 Mar;56(3):137-9 [16696516.001]
  • [Cites] Virchows Arch. 2006 Aug;449(2):148-58 [16758173.001]
  • [Cites] Int J Clin Oncol. 2007 Feb;12(1):56-8 [17380443.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2290-2 [10561286.001]
  • [Cites] Histopathology. 2001 Jun;38(6):510-8 [11422494.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):50-8 [11796841.001]
  • [Cites] Histopathology. 2002 Jul;41(1):1-29 [12121233.001]
  • [Cites] Drugs. 2002;62(14):2089-126 [12269857.001]
  • [Cites] Auris Nasus Larynx. 2002 Oct;29(4):401-3 [12393051.001]
  • [Cites] Oral Oncol. 2003 Jun;39(4):415-9 [12676264.001]
  • [Cites] Clin Pharmacokinet. 2003;42(5):419-36 [12739982.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):294-313 [9010103.001]
  • (PMID = 18761751.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Receptors, Complement 3d; 0 / Receptors, IgE; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC2556649
  •  go-up   go-down


Advertisement
4. Boniver V, Moreau P, Lefebvre P: Synovial sarcoma of the larynx: case report and literature review. B-ENT; 2005;1(1):47-51
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma of the larynx: case report and literature review.
  • Synovial sarcoma is a rare mesenchymal malignancy which represents 8.5% of all soft tissue sarcomas and usually occurs in the lower extremities of young adults.
  • We present here a case of aryepiglottic synovial sarcoma.
  • Complete surgical excision is the treatment of choice.
  • The role of chemotherapy and radiotherapy is still debated.
  • [MeSH-major] Laryngeal Neoplasms / epidemiology. Sarcoma, Synovial / epidemiology
  • [MeSH-minor] Adult. Endoscopy. Female. Humans. Laser Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999676.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 19
  •  go-up   go-down


5. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF: Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol; 2006 Feb;17(2):581-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
  • Median times to first skin and nonskin malignancies were compared between treatments using a survival analysis.
  • At 5 yr, the median time to a first skin carcinoma was delayed (491 versus 1126 d; log-rank test, P = 0.007), and the risk for an event was significantly lower with SRL-ST therapy (relative risk SRL-ST to SRL-CsA-ST 0.346; 95% confidence interval 0.227 to 0.526; P < 0.001, intention-to-treat analysis).
  • Nonskin cancers included those of the lung, larynx, oropharynx, kidney, gastrointestinal tract, prostate, breast, thyroid, and cervix as well as glioma, liposarcoma, astrocytoma, leukemia, lymphoma, and Kaposi's sarcoma.
  • Patients who received SRL-based, calcineurin inhibitor-free therapy after CsA withdrawal at month 3 had a reduced incidence of both skin and nonskin malignancies at 5 yr after renal transplantation compared with those who received SRL therapy combined with CsA.
  • [MeSH-minor] Adult. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Follow-Up Studies. Humans. Incidence. Risk Assessment

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434506.001).
  • [ISSN] 1046-6673
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


6. Altuğ T, Inci E, Güvenç MG, Edizer DT, Dervişoğlu S: Alveolar soft part sarcoma of the larynx. Eur Arch Otorhinolaryngol; 2007 Apr;264(4):445-9
Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar soft part sarcoma of the larynx.
  • Alveolar soft part sarcoma (ASPS) is a rare malignancy.
  • Surgery is accepted as the most effective treatment, radiotherapy and chemotherapy may be used as adjuvant treatments.
  • In this article, we report a case of ASPS occurring in the larynx, an extremely rare location for this rather unusual tumor.
  • To our knowledge, only three cases of laryngeal ASPS have been previously reported in the English literature.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Sarcoma, Alveolar Soft Part / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Disease Progression. Female. Hoarseness / diagnosis. Humans. Laryngectomy / methods. Laryngoscopy. Respiratory Sounds / diagnosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1331-5 [15956492.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1324-8 [12091061.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 1;136(1):1-9 [12165444.001]
  • [Cites] Med Pediatr Oncol. 1994;22(6):380-3 [7512190.001]
  • [Cites] Br J Oral Maxillofac Surg. 2001 Oct;39(5):394-7 [11601823.001]
  • [Cites] Ann Diagn Pathol. 2000 Jun;4(3):135-42 [10919382.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Jan;128(1):148-50 [12574775.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2004 Oct;68(10):1333-7 [15364506.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 May;34(3):268-72 [15741035.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(11):1511-6 [12855256.001]
  • [Cites] Int J Oral Maxillofac Surg. 2000 Oct;29(5):370-2 [11071242.001]
  • [Cites] Surg Neurol. 1998 Apr;49(4):441-4 [9537665.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Jan;99(1):64-70 [15599350.001]
  • [Cites] Ann Diagn Pathol. 2003 Oct;7(5):306-9 [14571434.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2004 May;68(5):569-71 [15081230.001]
  • [Cites] Otolaryngol Head Neck Surg. 1997 Dec;117(6):S95-7 [9419114.001]
  • [Cites] Br J Oral Maxillofac Surg. 1999 Dec;37(6):451-4 [10687905.001]
  • [Cites] Ann Diagn Pathol. 1999 Oct;3(5):315-7 [10556480.001]
  • [Cites] Cancer. 1952 Jan;5(1):100-11 [14886902.001]
  • (PMID = 17063352.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Hisada M, Biggar RJ, Greene MH, Fraumeni JF Jr, Travis LB: Solid tumors after chronic lymphocytic leukemia. Blood; 2001 Sep 15;98(6):1979-81
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second cancer risks for patients who received chemotherapy only as the first course of treatment (O/E = 1.21) were similar to risks for those who received no treatment initially (O/E = 1.19).
  • Significant excesses were found for Kaposi sarcoma (O/E = 5.09), malignant melanoma (O/E = 3.18), and cancers of the larynx (O/E = 1.72) and the lung (O/E = 1.66).
  • [MeSH-minor] Aged. Female. Humans. Male. Risk Factors. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / etiology. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11535538.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Pérez AF, Muñoz R, Morales J, Fereira E, Colina-Chourio J: [Transversal laryngotomy. Oncologic and functional results in laryngeal sarcoma. (Malignant fibrous histiocytoma). Case report and literature review]. Invest Clin; 2008 Mar;49(1):103-10
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transversal laryngotomy. Oncologic and functional results in laryngeal sarcoma. (Malignant fibrous histiocytoma). Case report and literature review].
  • [Transliterated title] Presentación de un caso de sarcoma maligno laríngeo, tratado mediante laringotomía transversa y revisión de la literatura.
  • Sarcomas of the larynx are rare neoplasmas that consitute less than 1% of laryngeal malignancies, and their usual treatment is surgery including partial and total laryngectomy and endoscopic laser cordotomy with reported 20% recurrence.
  • Due to previous positive experience from transversal laryngotomy in patients who underwent aritenoidectomy to treat bilateral cord paralysis after total thyroidectomy, the purpose of this work was to report on the surgical treatment of this rare case with such technique.
  • Thus, a 47 year-old physician who complained of hoarseness for four months without dyspnea, stridor, or dysphagia and with no history of irradiation or chemotherapy was operated after both endoscopic and tomographic studies showed a 3 to 4 cm glotic tumor in its right side, with no ulceration.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / surgery. Laryngectomy / methods. Sarcoma / diagnosis. Sarcoma / surgery

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18524336.001).
  • [ISSN] 0535-5133
  • [Journal-full-title] Investigación clínica
  • [ISO-abbreviation] Invest Clin
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Venezuela
  • [Number-of-references] 24
  •  go-up   go-down


9. Kollert M, Basten O, Delling G, Bockmühl U: [Clear cell chondrosarcoma of the larynx. A rare tumor in an uncommon location]. HNO; 2005 Apr;53(4):357-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell chondrosarcoma of the larynx. A rare tumor in an uncommon location].
  • [Transliterated title] Klarzellchondrosarkom des Larynx. Ein sehr seltener Tumor in einer aussergewöhnlichen Lokalisation.
  • So far, there have only been three cases of clear cell chondrosarcoma of the larynx published in the literature.
  • Diagnostic evaluation revealed a directly subglottic stenosis of the larynx, narrowing the lumen to 1/3.
  • The therapy of choice for this tumor is wide surgical resection.
  • Additional radio- and/or chemotherapy are not recommended.
  • Histologically, the clear cell chondrosarcoma can be easily confused with the highly malignant osteosarcoma or the conventional chondrosarcoma, both requiring more aggressive treatment.
  • [MeSH-major] Chondrosarcoma / diagnosis. Chondrosarcoma / surgery. Dyspnea / diagnosis. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / surgery. Laryngostenosis / diagnosis. Sarcoma, Clear Cell / diagnosis. Sarcoma, Clear Cell / surgery
  • [MeSH-minor] Humans. Laryngectomy. Male. Middle Aged. Rare Diseases / complications. Rare Diseases / diagnosis. Rare Diseases / surgery

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):386-92 [11859213.001]
  • [Cites] Eur Radiol. 1999;9(8):1625-8 [10525878.001]
  • [Cites] J Bone Joint Surg Am. 1976 Jul;58(5):676-83 [932066.001]
  • [Cites] Diagn Imaging Clin Med. 1986;55(4-5):219-27 [3533385.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):223-30 [6703199.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Jul;125(1):107-8 [11458227.001]
  • [Cites] Pathologe. 2000 Nov;21(6):449-55 [11148825.001]
  • [Cites] Skeletal Radiol. 1991;20(3):187-91 [2057790.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Jul;99(7 Pt 1):515-23 [2195959.001]
  • (PMID = 15316626.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Ozçelik T, Ali R, Ozkalemkaş F, Ozkocaman V, Coşkun H, Erişen L, Filiz G: A case of granulocytic sarcoma during complete remission of acute myeloid leukemia with multiple masses involving the larynx and nasopharynx. Kulak Burun Bogaz Ihtis Derg; 2003 Dec;11(6):183-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of granulocytic sarcoma during complete remission of acute myeloid leukemia with multiple masses involving the larynx and nasopharynx.
  • A thirty-seven-year-old male patient presented with dysphagia and hoarseness six months after complete remission of acute myeloid leukemia (AML-M0), which had been treated with chemotherapy.
  • Sagittal and axial magnetic resonance scans of the nasopharynx and neck showed a mass in the left retropharyngeal and perivertebral regions, 6x4 cm in size; another mass in the left vallecula, and infiltration of the right preepiglottic tissue by another mass of 2 cm.
  • A diagnosis of granulocytic sarcoma without leukemia relapse was made and the FLAG-Ida regimen was administered, after which partial regression of the masses was observed.
  • However, the patient died due to a pulmonary infection on the 17th day of chemotherapy.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Leukemia, Myeloid, Acute. Nasopharyngeal Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Deglutition Disorders / etiology. Diagnosis, Differential. Fatal Outcome. Hoarseness / etiology. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15567934.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Kohanawa R, Tabuchi K, Okubo H, Nagata M, Hara A: Primary osteogenic sarcoma of the ethmoid sinus: a case report. Auris Nasus Larynx; 2005 Dec;32(4):411-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary osteogenic sarcoma of the ethmoid sinus: a case report.
  • Primary osteogenic sarcoma arising from the ethmoid sinus is an extremely rare condition.
  • Computed tomography (CT) scan showed tumor calcification, which is a common feature of osteogenic sarcoma.
  • Exploratory ethmoidectomy was performed, and histological examination confirmed the diagnosis of osteogenic sarcoma.
  • Radiation therapy and chemotherapy failed to reduce the tumor size.
  • Although primary osteogenic sarcoma of the ethmoid sinus is uncommon, the authors emphasize that osteogenic sarcoma should be suspected when tumor calcification was observed on CT scan and that adequate surgical resection with negative surgical margins remains the mainstay of treatment of this lesion.
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / radiography. Neoplasms, Second Primary / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039814.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Shimomura S, Kikuchi Y, Oka S, Ishitoya J: Local treatment of AIDS-associated bulky Kaposi's sarcoma in the head and neck region. Auris Nasus Larynx; 2000 Oct;27(4):335-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local treatment of AIDS-associated bulky Kaposi's sarcoma in the head and neck region.
  • Kaposi's sarcoma (KS) is frequently seen in the head and neck regions of HIV-infected patients.
  • We treated the tongue lesion with intralesional chemotherapy.
  • Unless systemic chemotherapy is effective enough to improve a functional disorder, it is thought that local therapy employing excision or intralesional chemotherapy is one of the common therapeutic option of the otolaryngologist, because this treatment avoids severe side effects caused by systemic chemotherapy or radiotherapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Oropharyngeal Neoplasms / therapy. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / therapy. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Injections, Intralesional. Male. Tomography, X-Ray Computed. Vinblastine / administration & dosage. Vinblastine / therapeutic use


13. Manghani MK, Andrews J, Higgens CS: Kaposi's sarcoma in a patient with severe relapsing polychondritis. Rheumatol Int; 2004 Sep;24(5):309-11
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma in a patient with severe relapsing polychondritis.
  • This report describes the case of a young man who developed Kaposi's sarcoma (KS) after corticosteroid treatment for severe tracheal involvement of relapsing polychondritis (RP).
  • [MeSH-major] Adrenal Cortex Hormones / adverse effects. Immunosuppressive Agents / adverse effects. Polychondritis, Relapsing / drug therapy. Sarcoma, Kaposi / chemically induced. Sarcoma, Kaposi / virology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cyclophosphamide / adverse effects. Herpesvirus 8, Human / immunology. Humans. Larynx / immunology. Larynx / pathology. Larynx / physiopathology. Male. Trachea / immunology. Trachea / pathology. Trachea / physiopathology. Treatment Outcome

  • Genetic Alliance. consumer health - Relapsing polychondritis.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Baillieres Best Pract Res Clin Rheumatol. 2000 Mar;14(1):97-109 [10882216.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):1999-2008 [8669484.001]
  • [Cites] J Am Acad Dermatol. 1993 Nov;29(5 Pt 2):890-4 [8408835.001]
  • [Cites] Dermatologica. 1981;162(5):417-23 [7250476.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2859-61 [8194027.001]
  • [Cites] Medicine (Baltimore). 1976 May;55(3):193-215 [775252.001]
  • [Cites] Transplantation. 1999 Mar 15;67(5):648-52 [10096517.001]
  • [Cites] Rheumatology (Oxford). 2002 Jan;41(1):107-8 [11792889.001]
  • [Cites] Rev Rhum Ed Fr. 1993 Mar;60(3):240-4 [8293010.001]
  • [Cites] Transplantation. 2002 Jan 27;73(2):297-9 [11821747.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):500-17 [10649240.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Dermatology. 1997;194(2):180-2 [9094472.001]
  • (PMID = 14658005.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


14. Nakashima T, Kuratomi Y, Shiratsuchi H, Yamamoto H, Yasumatsu R, Yamamoto T, Komiyama S: Follicular dendritic cell sarcoma of the neck; a case report and literature review. Auris Nasus Larynx; 2002 Oct;29(4):401-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell sarcoma of the neck; a case report and literature review.
  • We report a case of FDC sarcoma arising in the neck.
  • Adjuvant chemotherapy of cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) was given.
  • Literature review provides the current information for the diagnosis and treatment of this unusual tumor.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radiography. Sarcoma / pathology. Sarcoma / radiography
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12393051.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 9
  •  go-up   go-down


15. Hosokawa S, Takebayashi S, Mineta H, Suzuki K, Baba S: Undifferentiated sarcoma of the maxillary sinus: report of a rare case in an adult. Auris Nasus Larynx; 2009 Feb;36(1):92-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undifferentiated sarcoma of the maxillary sinus: report of a rare case in an adult.
  • We accordingly diagnosed undifferentiated sarcoma in the maxillary sinus.
  • Combination chemotherapy with vincristine, doxorubicin, cyclophosphamide/ifosfamide with mesna and etoposide was administered; however, the tumor was unresponsive and the patient died after around 3 months.
  • [MeSH-major] Maxillary Sinus Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Ifosfamide / administration & dosage. Male. Mesna / administration & dosage. Middle Aged. Protective Agents / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18614305.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protective Agents; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


16. Boratyńska M, Watorek E, Smolska D, Patrzałek D, Klinger M: Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc; 2007 Nov;39(9):2736-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhibition of mTOR is a target for anticancer drugs in posttransplant malignancies.
  • The influence of conversion to sirolimus after malignancy diagnosis was investigated on patient and renal allograft survivals.
  • The 20 renal allograft recipients (4 women, 16 men) of ages 26 to 73 years (mean, 59 years) developed malignancies within 6 to 172 months (mean, 53 months) after transplantation.
  • Three patients developed posttransplant lymphoproliferative disease (PTLD); four, Kaposi sarcoma, three, lung cancer; two, malignant melanoma; two, breast cancer; two, renal cell carcinoma; one, Merkel cell carcinoma; one, cutaneous T-cell lymphoma; one, larynx cancer; and one, gingival cancer.
  • After tumor diagnosis, calcineurin inhibitors, azathioprine, or mycophenolate mofetil (MMF) were discontinued abruptly and sirolimus introduced (2 mg/d; target trough level, 4.0 to 8.0 ng/mL).
  • The observation time of sirolimus therapy was 4 to 48 months (mean, 14 months).
  • Two patients with PTLD (large B-cell lymphoma) and four with Kaposi sarcoma had full regressions.
  • Eleven patients (larynx cancer, melanoma, breast cancer, T-cell lymphoma, renal cell carcinoma, Merkel cell carcinoma, and skin lymphoma) in addition to sirolimus therapy, underwent oncologic treatment, namely, surgery and/or chemotherapy.
  • One patient with T-cell lymphoma lost his graft; in the remaining patients, serum creatinine level was stable.
  • In conclusion, Conversion to sirolimus resulted in regression of large B-cell lymphoma and Kaposi sarcoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Kidney Transplantation / adverse effects. Lymphoma, B-Cell / drug therapy. Neoplasms / drug therapy. Neoplasms / epidemiology. Postoperative Complications / drug therapy. Sarcoma, Kaposi / drug therapy. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunosuppressive Agents / therapeutic use. Lymphoproliferative Disorders / epidemiology. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous


17. Hatta C, Terada T, Okita J, Kakibuchi M, Kubota A, Sakagami M: Clinicopathological study of undifferentiated carcinoma of the parotid gland. Auris Nasus Larynx; 2003 Aug;30(3):273-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Undifferentiated carcinoma of the salivary gland is a rare malignant tumor, and is difficult to distinguish from other poorly differentiated types of carcinoma or sarcoma.
  • All patients died of distant metastasis despite radical surgery, suggesting that chemotherapy is needed to improve patient outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12927291.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Ulutin C, Cetinayak O, Aksu G, Fayda M, Ataergin S, Beyzadeoğlu M: Malignant peripheral primitive neuroectodermal (pPNET) of tongue. Auris Nasus Larynx; 2007 Mar;34(1):115-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors that once would have been diagnosed as Ewing's sarcoma are now often designated as peripheral neuroepithelioma or synonymously PNET.
  • The patient was treated with postoperative radiotherapy and chemotherapy.
  • Multiple liver metastases occurred 5 months after the initial diagnosis and following extensive chemotherapy the patient was only able to survive for a further 10 months.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fatal Outcome. Humans. Liver Neoplasms / secondary. Male. Neoplasms, Second Primary / pathology. Oral Surgical Procedures. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240098.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 15
  •  go-up   go-down


19. Sivanandan R, Kong CS, Kaplan MJ, Fee WE Jr, Thu-Le Q, Goffinet DR: Laryngeal embryonal rhabdomyosarcoma: a case of cervical metastases 13 years after treatment and a 25-year review of existing literature. Arch Otolaryngol Head Neck Surg; 2004 Oct;130(10):1217-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngeal embryonal rhabdomyosarcoma: a case of cervical metastases 13 years after treatment and a 25-year review of existing literature.
  • Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood, the majority of which are of the embryonal rhabdomyosarcoma (ER) variety.
  • Present day treatment protocols involve a combination of aggressive surgery, chemotherapy, and radiation therapy.
  • Embryonal rhabdomyosarcoma of the larynx is rare and unlike ER of other regions exhibits excellent response to multimodality treatment without the need for extensive surgery.
  • We report a case of cervical metastases in a 29-year-old man 13 years after treatment of his laryngeal ER.
  • To our knowledge, this is the first reported case of late neck metastases in ER of the larynx and the second reported case of delayed presentation of recurrent disease.
  • A 25-year review of all published reports of ER of the larynx was conducted that highlights the move toward organ preservation with the multimodality treatment protocols.
  • Embryonal rhabdomyosarcoma of the larynx is highly responsive to combination chemoradiotherapy, allowing for excellent cure rates without the need for extensive surgery.
  • [MeSH-major] Head and Neck Neoplasms / secondary. Laryngeal Neoplasms / pathology. Rhabdomyosarcoma, Embryonal / secondary

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492173.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


20. Biel MA: Photodynamic therapy of head and neck cancers. Methods Mol Biol; 2010;635:281-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of head and neck cancers.
  • The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma.
  • Several multi-institutional phase II clinical trials evaluating PDT treatment of head and neck cancers have demonstrated the efficacy of this minimally invasive therapy in the treatment of early oropharyngeal primary and recurrent cancers as well as the palliative treatment of refractory head and neck cancers.
  • Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT.
  • Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment.
  • Laryngeal cancers, comprising 171 patients in this group, obtained a durable complete response rate of 89% with up to a 16-year follow-up.
  • Photodynamic therapy is as effective as conventional therapies for the treatment of early (Cis, T1, T2) squamous cell cancers of the head and neck.
  • It is also a promising therapy to be used in association with surgery to increase tumor-free margins and therefore increase cure rates.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Photochemotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Randomized Controlled Trials as Topic. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552353.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Christensen NR, Charabi S, Johansen LS, Rygaard J, Balle VH, Tos M, Thomsen J: Effect of photodynamic therapy on a heterotransplanted human parotid tumor. Auris Nasus Larynx; 2000 Jul;27(3):241-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of photodynamic therapy on a heterotransplanted human parotid tumor.
  • To evaluate the effect of photodynamic therapy on human parotid tumors we used tumor specimens obtained from parotid surgery on a consecutive group of patients.
  • The original human tumors were pleomorphic adenoma (four), adenolymphoma (one), acinic cell carcinoma (one), sarcoma (one) and low-grade adenocarcinoma (one).
  • We re-implanted this tumor on ten mice bilaterally, and treated the tumors with photodynamic therapy (PDT), resulting in a mean depth of tumor necrosis of 5.4 mm (1-10 mm).
  • In three cases we found vital tumor cells in the periphery of the tumor after treatment, with several new blood vessels in the surrounding tissue, indicating a great potential for neo-angiogenesis in this tumor.
  • In order to evaluate the possible nerve damage subsequent to the photodynamic therapy, the ischiadic nerve in 24 lower limbs of nude mice were investigated.
  • The current study demonstrates that the nude mice implantation model is excellent to investigate growth in both malignant and benign parotid tumors, and to test new therapeutic modalities.
  • Photodynamic therapy seems to have a possible role in the future management of the malignant lesions of the parotid gland, in cases where radical surgery for some reason is not achievable.
  • [MeSH-major] Neoplasm Transplantation. Parotid Neoplasms / drug therapy. Photochemotherapy. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10808112.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down






Advertisement